Transcatheter interventional management of postoperative residual shunt lesion after congenital cardiac surgery
Main Article Content
Abstract
Background: Congenital heart defects can be effectively managed through a variety of approaches, including conservative treatment, surgery, or interventional procedures. Complex defects, such as ventricular or atrial septal defects and patent ductus arteriosus, often necessitate congenital cardiac surgery for correction. Residual lesions refer to defects that persist after surgery or develop later on. Hemodynamically significant residual shunts should be addressed through either transcatheter interventions or redo surgery. Transcatheter closure is increasingly favored as it is less invasive, has a high safety profile, and typically results in lower morbidity, faster recovery times, and reduced costs compared to traditional redo open-heart surgery. This approach allows for effective management of congenital heart defects while minimizing the impact on the patient's overall health. This study aimed to understand the outcomes of these transcatheter management strategies, providing insight into effective clinical practices for managing post-surgical congenital cardiac shunt lesions.
Methods: The patients who developed residual lesion after cardiac surgical correction of shunt lesion like ventricular septal defect (VSD), arterial switch operation (ASO) with atrial septal defect (ASD), ASD with mitral valve cleft, patent ductus arteriosus (PDA) ligation were included. This is a prospective observational study which was done in National Heart Foundation Hospital & Research Institute during 2014 August to 2024 September.
Results: Among the seven patients with post-operative residual shunt lesions, four were male and three were female, with a median age of 11 years, ranging from 1 to 28 years. Six of these patients (85.7%) underwent elective closures, while one required an emergency intervention (14.3%). On average, the interval between surgery and the subsequent transcatheter intervention was 6.6 years, with a range from 15 days to 13 years. The average hospital stay across all cases was 7 days, varying from 4 to 22 days, and the follow-up duration averaged 5.84 years. Among these patients, one individual with VSD had a residual shunt. Importantly, there were no vascular access-related complications, postprocedural heart block, hemolysis, significant new valvular regurgitation, or procedure-related mortality.
Conclusion: Transcatheter-based interventions are typically the first-line treatment for newly diagnosed cases. Here a few rare interventional techniques have demonstrated successfully resolved complex surgical complications, ensuring optimal patient outcomes with minimal risks.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Murphy JG, Gersh BJ, McGoon MD, et al. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med 1990;323:1645–1650
3. Sorensen KE, Kristensen B, Hansen OK. Frequency of occurrence of residual ductal flow after surgical ligation by color-flow mapping. Am J Cardiology. 1991;67:653–654.
4. Perlof JK, Warnes CA. Challenges posed by adults with repaired congenital heart disease. Circulation 2001;103:2637- 43.
5. Gokalp S, Guler Eroglu A, Saltik L, et al. Relationships between left heart chamber dilatation on echocardiography and left-to-right ventricle shunting quantified by cardiac catheterization in children with ventricular septal defects. Pediatr Cardiol 2014;35:691-8.
6. Knauth AL, Lock JE, Perry SB, et al. Transcatheter device closure of congenital and postoperative residual ventricular septal defects. Circulation 2004;110:501-7
7. Carminati M, Butera G, Chessa M, et al. Transcatheter closure of congenital ventricular septal defects: results of the European Registry. Eur Heart J 2007;28:2361-8.
8. Carminati M, Butera G, Chessa M, et al. Transcatheter closure of congenital ventricular septal defect with Amplatzer septal occluders. Am J Cardiol 2005;96:52L-8L.
9. Sugita T, Ueda Y, Matsumoto M, et al. Repeated procedure after radical surgery for tetralogy of Fallot. Ann Thorac Surg. 2000 Nov 1;70(5):1507–1510
10. Pedra CA, Pontes SC Jr, Pedra SR, Salerno L, Sousa JB, Miaira MA, et al. Percutaneous closure of postoperative and post-traumatic ventricular septal defects. J Invasive Cardiol. 2007;19:491–5.
11. Shuhaiber J, Gauvreau K, Thiagarjan R, et al. Congenital heart surgeon’s technical proficiency affects neonatal hospital survival. J Thorac Cardiovasc Surg 2012; 144(5):1119–1124. [PubMed: 22421402] Nathan et al. Page 10 J Am Coll Cardiol. Author manuscript; available in PMC 2022 May 18.
12. Karamichalis JM, Thiagarajan RR, Liu H, Mamic P, Gauvreau K, Bacha EA. Stage I Norwood: Optimal Technical Performance improves outcomes irrespective of preoperative physiologic status or case-complexity. J Thorac Cardiovasc Surg 2010; 139(4):962–968. [PubMed: 20074754]
13. Gupta SK, Sivasankaran S, Bijulal S, Tharakan JM, Harikrishnan S, Ajit K. Trans-catheter closure of atrial septal defect: balloon sizing or no balloon sizing - single centre experience. Ann Pediatr Cardiol 2011;4:28-33.
14. Zhou W, Li F, Fu L, et al. Clinical Experience of Transcatheter Closure for Residual Ventricular Septal Defect in Pediatric Patients. Congenit Heart Dis 2016;11:323-31.
15. Kouakou NYN, Song J, Huh J, et al. The experienceof transcatheter closure of postoperative ventricular septal defect after total correction. J Cardiothorac Surg 2019;14:104.
16. Dua JS, Carminati M, Lucente M, et al. Transcatheter closure of postsurgical residual ventricular septal defects: early and mid-term results. Catheter Cardiovasc Interv 2010;75:246-55.
17. Dodge-Khatami A, Knirsch W, Tomaske M, Pretre R, Bettex D, Rousson V, et al. Spontaneous closure of small residual ventricular septal defects after surgical repair. Ann Thorac Surg. 2007;83:902–5.
18. Paç A, Polat TB, Çetin İ, Oflaz MB, Ballı S. Figulla ASD occluder versus Amplatzer Septal Occluder: a comparative study on validation of a novel device for percutaneous closure of atrial septal defects. J Interv Cardiol 2009;22:489-95.
19. Ramakrishnan S, Saxena A, Choudhary SK. Residual VSD closure with an ADO II device in an infant. Congenit Heart Dis. 2011;6:60–3.
20. Yin S, Zhu D, Lin K, An Q. Perventricular device closure of congenital ventricular septal defects. J Card Surg. 2014;29:390–400.
21. Egbe AC, Poterucha JT, Rihal CS, Taggart NW, Cetta F, Cabalka AK, et al. Transcatheter closure of postmyocardial infarction, iatrogenic, and postoperative ventricular septal defects: the Mayo Clinic experience. Catheter Cardiovasc Interv. 2015;86:1264–70.stry. Eur Heart J. 2007;28:2361–8.
22. Sudhakar BG. Percutaneous transcatheter closure of a distorted residual patent ductus arteriosus post surgical ligation using retrograde wiring and femoral arterio-venous loop technique-a case report. IHJ Cardiovascular Case Reports (CVCR). 2018 Oct 1;2(3):208–210. https://doi.org/10.1016/j.ihjccr.2018.04.008
23. Baspinar Osman, Kilinc Metin, Kervancioglu Mehmet, Indem Ahmet. Transcatheter closure of a residual PDA after surgical ligation in children. Korean Circ. J. 2011;41(Nov (11)):654–657.
24. Lloyd TR, Beekman RH 3rd. Clinically silent patent ductus arteriosus. Am Heart J 1994;127:1664-5.
25. Gu X, Zhang Q, Sun H, et al. Transcatheter closure versus repeat surgery for the treatment of postoperative left-to-right shunts: A single center 15-year experience. Cardiol Res. 2017 Dec;8(6):286–292. https://doi.org/10.14740/cr629e